Development of somatostatin based radiopharmaceuticals for receptor mediated radionuclide therapy
Carregando...
Data
2007
Data de publicação:
Orientador
Título da Revista
ISSN da Revista
Título do Volume
É parte de
Comparative Evaluation of Therapeutic Radiopharmaceuticals
É parte de
É parte de
Exportar
Resumo
The paper describes the methodology used for and the results of labelling
[Tyr3
]octreotate (TATE) with radioiodine (131I) and [DOTA,Tyr3
]octreotate
(DOTATATE) with 131I and lutetium (177Lu). The quality control and purification
procedures are also described. Biodistribution studies were performed in normal Swiss
mice and in nude mice bearing AR42J tumours. In vitro studies were used to evaluate
the affinity of the radiopharmaceuticals for somatostatin receptors in rat brain cortex
and tumour cells. Saturation binding and the internalization of the labelled peptides
were determined. The frequency of micronuclei in peripheral blood lymphocytes
exposed to different radioactive concentrations of [131I]DOTATATE and
[
177Lu]DOTATATE was evaluated by micronucleus assay.
Como referenciar
ARAUJO, E.B.; CALDEIRA FILHO, J.S.; NAGAMATI, L.T.; MURAMOTO, E.; COLTURATO, M.T.; COUTO, R.; OKASAKI, K.; SUZUKI, M.F.; GUIMARAES, M.I.C.C. Development of somatostatin based radiopharmaceuticals for receptor mediated radionuclide therapy. Comparative Evaluation of Therapeutic Radiopharmaceuticals. p. 27-52. Disponível em: http://repositorio.ipen.br/handle/123456789/23066. Acesso em: 13 Feb 2025.
Esta referência é gerada automaticamente de acordo com as normas do estilo IPEN/SP (ABNT NBR 6023) e recomenda-se uma verificação final e ajustes caso necessário.